Drug Type Small molecule drug |
Synonyms Atecegatran Metoxil, AR-H065522, AZD-0837 + [1] |
Target |
Action inhibitors |
Mechanism thrombin inhibitors(Factor IIa inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H23ClF2N4O5 |
InChIKeyXSNMGLZVFNDDPW-ZWKOTPCHSA-N |
CAS Registry433937-93-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Embolism | Phase 2 | Denmark | 01 Oct 2007 | |
Embolism | Phase 2 | Norway | 01 Oct 2007 | |
Embolism | Phase 2 | Poland | 01 Oct 2007 | |
Embolism | Phase 2 | Russia | 01 Oct 2007 | |
Embolism | Phase 2 | Sweden | 01 Oct 2007 | |
Embolism | Phase 2 | United Kingdom | 01 Oct 2007 | |
Stroke | Phase 2 | - | 01 Feb 2007 | |
Systemic embolism | Phase 2 | - | 01 Feb 2007 | |
Atrial Fibrillation | Phase 2 | Denmark | 01 Sep 2005 | |
Atrial Fibrillation | Phase 2 | Finland | 01 Sep 2005 |
Phase 2 | 523 | (AZD0837) | bewrovhrvu = omxanajeqa hrqgkcvltp (wuwttepjgl, sfbwopslyw - cwvcyfdyyo) View more | - | 06 Mar 2012 | ||
Vitamin K (VKA, INR 2-3) | bewrovhrvu = irdnopccyj hrqgkcvltp (wuwttepjgl, hdzbinalbg - fpgckazfet) View more | ||||||
Phase 2 | 955 | Vitamin K antagonists | ercaeldmay(eakzshsrzv) = wysteagmaq icnpiuwbwu (spkpyxlhof ) | - | 01 Dec 2009 |